Clinical trials
Immune Checkpoint Inhibitors (ICIs) clinical trials
Below are recruiting immune checkpoint inhibitors (icis) clinical trials, each written for real people, not researchers. We’re tracking 70 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04977791Recruiting
Study how drug resistance develops in lung cancer immunotherapy
This study looks at lung tumor tissue and blood to understand why immune checkpoint drugs can stop working in non-small cell lung cancer. It may help researchers find better ways to predict and overcome drug resistance.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06519292Recruiting
Heart side effects from immunotherapy in cancer patients
This trial looks at whether immunotherapy drugs (checkpoint inhibitors) cause heart problems in people with certain cancers. It will help doctors understand who is at risk and how to monitor for side effects.
Amsterdam, North HollandAges 50 years+ - NCT07004868Recruiting
Inflammation & treatment response in lung cancer immunotherapy
This study looks at how inflammation and body changes (like weight loss) affect how well immunotherapy works in lung cancer. If you are starting immunotherapy at the hospital in Tours, your doctors will collect information from your regular care to learn more about your response.
ToursAges 18 years+ - NCT06675643Recruiting
Remote monitoring of side effects from melanoma treatment
This study tests a smartphone app called Vigilant that helps monitor side effects from a melanoma treatment (ipilimumab and nivolumab). You may be able to join if you are about to start this therapy.
Rochester, MinnesotaAges 18 years+ - NCT06472245RecruitingPhase 3
Cancer vaccine for lung cancer that stopped responding to immunotherapy
This trial tests a therapeutic cancer vaccine called OSE2101 for people with advanced non-small cell lung cancer whose tumors stopped responding to an immunotherapy drug. The vaccine is designed to help your immune system fight the cancer in a different way.
Beverly Hills, CaliforniaAges 18 years+ - NCT06475807Recruiting
Dietary changes for people on immunotherapy for cancer
This study tests whether a change in diet can help people with early-stage melanoma or lung cancer who are receiving immunotherapy (a type of treatment that helps your immune system fight cancer). You will be asked to follow a diet, give blood and stool samples, and complete questionnaires to see how the diet affects your body and treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT06349642Recruiting
Testing a live tumor test for immune therapy response
This trial uses a special test on live tumor samples to see if it can predict how well immune checkpoint inhibitors (a type of immunotherapy) will work for different cancers. It may help doctors choose the best treatment for you.
Phoenix, ArizonaAges 18 years+ - NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Ho Chi Minh City, Hồ Chí MinhAges 18–80 - NCT06132698RecruitingPhase 2
Immunotherapy injected into spinal fluid for lung cancer that has spread to the brain lining
This trial tests giving an immunotherapy drug directly into the spinal fluid for people with non-small cell lung cancer that has spread to the lining of the brain or spinal cord. The goal is to see if this approach can help control the cancer while allowing you to continue other treatments you may already be taking.
Chengdu, SichuanAges 18–75 - NCT05335928RecruitingPhase 3
Abatacept for immune-therapy heart inflammation in hospitalized adults
This Phase 3 trial tests abatacept to treat myocarditis (inflammation of the heart muscle) caused by immune checkpoint cancer medicines. It may help patients recover faster and safely manage this serious side effect while they are in the hospital.
Los Angeles, CaliforniaAges 18 years+ - NCT05283226RecruitingPhase 2
Oral anti-cancer pill plus paclitaxel after immunotherapy failure
This Phase 2 trial studies an oral study drug (NRC-2694-A) given with paclitaxel to treat head and neck squamous cell cancer that has come back or spread after immunotherapy. It tests whether this combination is safer and works better than expected for people whose cancer progressed on immune checkpoint inhibitors.
Fullerton, CaliforniaAges 18 years+ - NCT04871542Recruiting
Predicting risk of immune therapy side effects
This study tries to predict who is more likely to get serious side effects from immune checkpoint medicines used for solid tumors. You may help researchers by answering questionnaires before treatment and during follow-up, and by possibly storing sample specimens.
Anchorage, AlaskaAges 18 years+ - NCT04038619RecruitingPhase 1
Fecal transplant for immune-therapy diarrhea or bowel inflammation
This early-phase study tests whether stool/fecal microbiota transplant (a fecal transplant) can help people who develop significant diarrhea or colitis after immune-checkpoint therapy. It aims to reduce bowel inflammation and improve symptoms, while carefully checking for infections.
Houston, TexasAges 18 years+ - NCT07421869Recruiting
Recovery from immune therapy-related hypothyroidism
This trial looks at whether patients can recover from low thyroid function caused by immune checkpoint inhibitor drugs. If you've finished immune therapy and are on thyroid medication, you may be able to stop or reduce it.
Seongnam-siAges 19 years+ - NCT07381634RecruitingPhase 2
Testing ondansetron to reduce immunotherapy side effects in liver cancer
This study tests whether adding ondansetron (a common anti-nausea drug) can reduce side effects from immunotherapy in people with liver cancer. If you are starting a specific combination treatment for liver cancer, you may be eligible.
Wenzhou, ZhejiangAges 18–80 - NCT06807593RecruitingPhase 2
Treating ICI-related diarrhea or colitis with ustekinumab
This trial tests if ustekinumab can help cancer patients who have diarrhea or colitis caused by immune checkpoint inhibitors. It may be an option if standard treatments haven't worked or aren't suitable.
Houston, TexasAges 18 years+ - NCT06581406RecruitingPhase 2/Phase 3
RP2 with nivolumab for untreated uveal melanoma
This clinical trial tests a new treatment called RP2 (a virus that attacks cancer cells) combined with nivolumab (an immunotherapy drug) for people with metastatic uveal melanoma who have never had immunotherapy before. It aims to see if this combination can shrink tumors and improve outcomes.
Scottsdale, ArizonaAges Any age - NCT06860542RecruitingPhase 2
Inhaled steroid to prevent lung inflammation from returning after immunotherapy
This trial tests whether using an inhaled steroid (budesonide) can help prevent lung inflammation (pneumonitis) from coming back in people who have had it caused by immunotherapy cancer treatment. It may be an option for patients who need extra support after their first bout of this side effect.
Calgary, AlbertaAges 18 years+ - NCT06635954Recruiting
Blood test to predict response to immunotherapy
This study is testing a blood test (Episwitch CiRT®) that looks at your DNA to see if it can predict whether you will respond to a type of immunotherapy called PD-(L)-1 checkpoint inhibitors. The goal is to see if this test is accurate across many different types of cancer.
Norwich, ConnecticutAges 18 years+ - NCT06324240RecruitingPhase 1
Personalized vaccine plus immunotherapy for triple-negative breast cancer
This trial tests a personalized vaccine made from your tumor combined with immunotherapy drugs (pembrolizumab or ipilimumab) for triple-negative breast cancer. It aims to help your immune system recognize and attack cancer cells.
Atlanta, GeorgiaAges 18 years+ - NCT05481658RecruitingPhase 1
DPCP plus immunotherapy for skin cancer spread to the skin
This Phase 1 study tests a skin-applied treatment called DPCP added to standard PD-1/PD-L1 immunotherapy for cancers that have spread to the skin. It aims to improve control of skin tumors while checking safety and how well the immune system responds.
New York, New YorkAges 18 years+ - NCT05484908Recruiting
Tested treatment for hepatitis B-related liver cancer after immunotherapy
This trial studies whether the ALSS treatment is safe and effective for people with hepatitis B-related hepatocellular carcinoma who recently received immune checkpoint inhibitors. It may help improve outcomes for certain liver-related complications after immunotherapy, based on how their liver tests look.
Guangzhou, GuangdongAges 18–65
Hear when a new Immune Checkpoint Inhibitors (ICIs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune checkpoint inhibitors (icis)?
- Yes. Clin2 currently lists 70 recruiting immune checkpoint inhibitors (icis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune checkpoint inhibitors (icis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune checkpoint inhibitors (icis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.